JP2011507888A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507888A5
JP2011507888A5 JP2010539814A JP2010539814A JP2011507888A5 JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5 JP 2010539814 A JP2010539814 A JP 2010539814A JP 2010539814 A JP2010539814 A JP 2010539814A JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5
Authority
JP
Japan
Prior art keywords
compound
imidazo
phenylamino
pyridine
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010539814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507888A (ja
JP5710268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/087476 external-priority patent/WO2009085980A1/en
Publication of JP2011507888A publication Critical patent/JP2011507888A/ja
Publication of JP2011507888A5 publication Critical patent/JP2011507888A5/ja
Application granted granted Critical
Publication of JP5710268B2 publication Critical patent/JP5710268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010539814A 2007-12-19 2008-12-18 ８−アニリノイミダゾピリジン及びその抗ガン及び／又は抗炎症剤としての使用 Expired - Fee Related JP5710268B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1515507P 2007-12-19 2007-12-19
US61/015,155 2007-12-19
US5402408P 2008-05-16 2008-05-16
US61/054,024 2008-05-16
PCT/US2008/087476 WO2009085980A1 (en) 2007-12-19 2008-12-18 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents

Publications (3)

Publication Number Publication Date
JP2011507888A JP2011507888A (ja) 2011-03-10
JP2011507888A5 true JP2011507888A5 (cg-RX-API-DMAC10.html) 2012-02-23
JP5710268B2 JP5710268B2 (ja) 2015-04-30

Family

ID=40404998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539814A Expired - Fee Related JP5710268B2 (ja) 2007-12-19 2008-12-18 ８−アニリノイミダゾピリジン及びその抗ガン及び／又は抗炎症剤としての使用

Country Status (16)

Country Link
US (1) US8293763B2 (cg-RX-API-DMAC10.html)
EP (1) EP2231662B1 (cg-RX-API-DMAC10.html)
JP (1) JP5710268B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100101666A (cg-RX-API-DMAC10.html)
CN (1) CN101903387B (cg-RX-API-DMAC10.html)
AT (1) ATE513832T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008343062B2 (cg-RX-API-DMAC10.html)
CA (1) CA2704125A1 (cg-RX-API-DMAC10.html)
DK (1) DK2231662T3 (cg-RX-API-DMAC10.html)
IL (1) IL205490A (cg-RX-API-DMAC10.html)
NZ (1) NZ585306A (cg-RX-API-DMAC10.html)
PL (1) PL2231662T3 (cg-RX-API-DMAC10.html)
PT (1) PT2231662E (cg-RX-API-DMAC10.html)
RU (1) RU2498985C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009085980A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201003046B (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5421925B2 (ja) * 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (cg-RX-API-DMAC10.html) 2011-07-01 2018-04-28
IN2014CN02646A (cg-RX-API-DMAC10.html) 2011-09-14 2015-08-07 Samumed Llc
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
KR101223245B1 (ko) * 2012-09-12 2013-01-17 삼부기술 주식회사 영상이미지의 기준점 대비 도화하기 위한 대상 지형지물을 촬영하는 공간 영상도화 시스템
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015057823A1 (en) 2013-10-15 2015-04-23 Radux Devices, LLC Securing a medical device to a valve instrument
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
CN108358939A (zh) * 2014-07-29 2018-08-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
WO2017079765A1 (en) 2015-11-06 2017-05-11 Samumed, Llc Treatment of osteoarthritis
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
MD3464285T2 (ro) 2016-06-01 2023-01-31 Biosplice Therapeutics Inc Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei
CN110709082A (zh) 2016-10-21 2020-01-17 萨穆梅德有限公司 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
JP7630905B2 (ja) 2016-11-07 2025-02-18 バイオスプライス セラピューティクス インコーポレイテッド 単回用量の調整済み注射用製剤
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
HUP0401292A3 (en) * 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
JP3764440B2 (ja) * 2002-05-24 2006-04-05 日東電工株式会社 光学フィルムの製造方法
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
AU2004293018B2 (en) * 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
ATE443063T1 (de) * 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen

Similar Documents

Publication Publication Date Title
JP2011507888A5 (cg-RX-API-DMAC10.html)
JP2011526926A5 (cg-RX-API-DMAC10.html)
JP2009507909A5 (cg-RX-API-DMAC10.html)
JP2011526924A5 (cg-RX-API-DMAC10.html)
JP2015511638A5 (cg-RX-API-DMAC10.html)
JP2011529073A5 (cg-RX-API-DMAC10.html)
JP2007505877A5 (cg-RX-API-DMAC10.html)
JP2013010792A5 (cg-RX-API-DMAC10.html)
EA036446B1 (ru) Соединения и композиции для подавления активности shp2
JP2005519932A5 (cg-RX-API-DMAC10.html)
JP2008526999A5 (cg-RX-API-DMAC10.html)
JP2008195730A5 (cg-RX-API-DMAC10.html)
JP2016506387A5 (cg-RX-API-DMAC10.html)
RU2008142841A (ru) СОЕДИНЕНИЯ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ ГАМКА РЕЦЕПТОРОВ
JP2005511531A5 (cg-RX-API-DMAC10.html)
JP2012041365A5 (cg-RX-API-DMAC10.html)
JP2008509187A5 (cg-RX-API-DMAC10.html)
JP2011507896A5 (cg-RX-API-DMAC10.html)
JP2009526831A5 (cg-RX-API-DMAC10.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2007515476A5 (cg-RX-API-DMAC10.html)
JP2012510990A5 (cg-RX-API-DMAC10.html)
JP2011505356A5 (cg-RX-API-DMAC10.html)
CN1638739A (zh) 治疗成瘾性障碍的化合物
CA2728098A1 (en) Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor